					1	Complete if Known							
Substitute for form 1449/PTO (Revised 07/2007)  INFORMATION DISCLOSURE						pplication N	umh		10/599,448				
						ling Date	uiiio	<u> </u>	03/08/2007				
						rst Named In	nven	tor	Pascal Drevet				
						rt Unit	17011	101	1648		· · · · · · · · · · · · · · · · · · ·		
STAT	EM	E	T	BY APPLICANT	7 1				1046				
(Use as many sheets as necessary)						Examiner Name			Stuart Snyder				
Sheet 1 of 1						Attorney Docket Number			033339/317269				
		·····			. S. I	PATENT DO	OCU	MENT	S				
Examiner	Cita	Document Number Cite				Publication Data Nam			e of Patentee or Pages, Colu			I inas Whara	
Examiner Initials*		<b>I</b>		Number - Kind Code (if known)		Publication Date MM-DD-YYYY		Name of Patentee or Applicant of Cited Document		Relevant Passages of Re			
										Figures Appear			
			US-										
			US-										
											****		
			US-								······································		
FOREIGN PATENT DOCUMENTS  Foreign Patent Document Pages, Columns, Lines, English													
Examiner	Cite		Foreign Patent Document			Publication Da		Name of Patentee or		Where Relevant		English Language	
Initials	No.		Country Code - Number Kind Cod		ie			1	nt of Cited	Passages or Relevant		Translation	
			(if known)					Document		Figures Appear		Attached	
										1			
					·								
					ОТ	HER DOC	UMI	ENTS					
En												English	
				•		CAPITAL LETTERS), title of the article (when appropriate), title of the serial, symposium, catalog, etc.), date, page(s), volume-issue number(s),						Language	
Examiner		Cite	publisher, city and/or country v					эв, •ю.,, ч	are, page(e), voian	ie issae namoei	(5),	Translation Attached	
Initials*		No.										Attached	
		1		L. STEINAA, A.M. SERENSEN, J.O. NIELSEN, and JE.S. HANSEN;									
				"Antibody to HIV-1 Tat protein inhibits the replication of virus in culture"; ARCHIVES OF VIROLOGY; SPRINGER-VERLAG 1994, PRINTED IN									
				AUSTRIA; Vol. 139; pages 263-271.									
						AL.; "Tat-specific cytotoxic T lymphocytes select for SIV							
				escape variants during resolution of primary viraemia"; NATURE; Vol. 147;									
		September 21, 2000; pag			ges 3	ges 386-390.							
		3		ALAIN LECOQ, ET AL.; "Increasing the humoral immunogenic properties of the									
				HIV-1 Tat protein using a ligand-stabilizing strategy; VACCINE; 2008; Vol. 26;									
				Pages 2615-2626.									
		4		SABRINA TURBANT, ET AL.; "Cynomolgus macaques immunized with two HIV-1 Tat stabilized proteins raise strong and long-lasting immune responses with a pattern of Th1/Th2 response differing from that in mice; VACCINE; 2009;									
				doi:10.1016/j.vaccine.2009.06.083.								***************************************	
		5		"Effect of a heparin fragment (Hep6000) on HIV VPR and Nef Immunogenicity".									
Examiner	$\dashv$		I					Date			L		
Signature								Consid	ered				

<sup>\*</sup>Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.